Evolent Health (EVH) Stock
Healthcare tech firm supporting value based care. Here's the price, business snapshot, and what's worth knowing about Evolent Health in September 2026.
Evolent Health, Inc. (EVH) is a US healthcare technology and services company focused on helping payers and providers transition to value‑based care. It combines analytics, care management platforms and operational services to support risk‑bearing contracts and population health initiatives. Investors should know Evolent generates recurring, contract-driven revenue from long-term engagements, which can provide some stability, but performance depends on successful contract execution and client retention. Key growth levers include the broader shift towards value-based reimbursement, expanded provider partnerships and technology adoption. Primary risks include regulatory or reimbursement changes, competition from larger healthcare IT firms, margin pressure if care outcomes are worse than expected, and stock volatility typical of mid-cap healthcare names. This overview is educational, not personalised investment advice; investors should evaluate financials, management commentary and sector trends, and consider seeking independent financial advice before making decisions.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Evolent Health's stock, with a target price of $14.4, indicating growth potential.
Financial Health
Evolent Health is performing well with strong revenue and cash flow, though margins could improve.
Dividend
Evolent Health's projected dividend of $0.12 results in a below-average yield, making it less attractive for dividend-seeking investors. If you invested $1000 you would be paid $1.20 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Value‑based care tailwind
The shift to value‑based reimbursement can increase demand for Evolent's services, though adoption rates and reimbursement rules can vary and affect outcomes.
Technology plus services
A combined software and services model offers recurring revenue potential, but execution and contract performance remain critical to margin and growth.
Policy and payer dynamics
Regulatory, payer and market changes can materially influence results — investors should watch policy shifts and payer relationships carefully.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
